INCY – incyte corporation (US:NASDAQ)

DELAYED
$ usd
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
1D
5D
1M
3M
YTD
1Y
3Y
1 Day INCY SPY QQQ SPX
Date
Time
Symbol
Company Name
Action
%Chg
4/30/2024
07:00 am
incy
incyte corporation
MISS
-1.8%
2/13/2024
07:00 am
incy
incyte corporation
BEAT
0.2%
10/31/2023
07:00 am
incy
incyte corporation
BEAT
3.0%
8/1/2023
07:00 am
incy
incyte corporation
BEAT
-3.5%
Earnings are essential to understanding the financial health of a company listed on any Stock Exchange. But what are Earnings, how are they calculated, when are they announced, and how are they used to make sound investment decisions?
The answers are right here.
Stock Stats
News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
Order Stats
Sub-Penny
Odd Lot
Avg. bid-ask spread
Avg. bid / ask size
Shares at ask / bid
Off exchange
Top News Gainers
4/5 Incyte Announces First Presentation of Phase 3 Data from the TRuE-AD Program of Ruxolitinib Cream at the Revolutionizing Atopic Dermatitis Virtual Symposium 7.1%
7/30 Incyte Reports 2019 Second Quarter Financial Results and Provides Updates on Key Clinical Programs 6.4%
3/13 Incyte Co. (NASDAQ: INCY) was upgraded by analysts at Bank of America Corp from a "neutral" rating to a "buy" rating. They now have a $83.00 price target on the stock. 6.4%
3/26 Incyte Names New Member to Its Board of Directors 5.9%
1/13 Incyte Co. (NASDAQ: INCY) had its "buy" rating re-affirmed by analysts at Cowen Inc. 5.7%
11/25 Data from Incyte’s Oncology Portfolio Accepted for Presentation at the 61st Annual ASH Meeting 5.3%
4/15 Form 4 INCYTE CORP For: Apr 13 Filed by: Pasquale Maria E 5.2%
2/18 Form 4 INCYTE CORP For: Feb 13 Filed by: Pasquale Maria E 4.0%
9/19 Form 4 INCYTE CORP For: Sep 18 Filed by: SWAIN PAULA J 4.0%
3/24 Blair likes Incyte in premarket analyst action [Seeking Alpha] 3.5%
Top News Decliners
1/2 Incyte Announces Results of Phase 3 Study of Itacitinib in Patients with Treatment-Naïve Acute Graft-Versus-Host Disease -9.4%
5/10 Form 4 INCYTE CORP For: May 09 Filed by: Iyengar Vijay K -6.1%
3/26 Form 8-K INCYTE CORP For: Mar 25 -5.6%
6/7 Form SC 13D/A INCYTE CORP Filed by: BAKER BROS. ADVISORS LP -5.0%
9/23 Incyte to Host Investor Conference Call from ESMO 2019 -4.6%
1/28 Incyte's skin disease drug meets main goal in late-stage study [Reuters] -3.8%
3/10 Incyte Joins Elite List Of Stocks With 95-Plus Composite Rating [Investor's Business Daily] -3.2%
9/27 Incyte Announces Positive Updated Results from Phase 2 Trial of Pemigatinib in Patients with Previously Treated, Advanced Cholangiocarcinoma -3.2%
9/12 Incyte Co. (NASDAQ: INCY) is now covered by analysts at BMO Capital Markets. They set a "market perform" rating on the stock. -3.1%
8/27 BriaCell Announces Participation at the 21st Annual Global Investment Conference in New York City September 8-10, 2019 -3.1%

Don’t Miss Out On The Next BIG Stock Move

Thanks for submitting the form.
INCY – incyte corporation (US:NASDAQ)
DELAYED
$ usd
1D
5D
1M
3M
YTD
1Y
3Y
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
INCY
SPY
QQQ
SPX
INCY – incyte corporation (US:NASDAQ)
DELAYED
$ usd
1D
5D
1M
3M
YTD
1Y
3Y
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
INCY SPY QQQ SPX
Stock Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
Sub-Penny
Odd Lot
Avg. bid-ask spread
Avg. bid / ask size
Shares at ask / bid
Off exchange
Stock Stats
Order Stats
Sub-Penny
Odd Lot
Avg. bid-ask spread
Avg. bid / ask size
Shares at ask / bid
Off exchange
News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
News
5/15
08:48 am
incy
Low
How Does Incyte Stock's Decline During The 2022 Inflation Shock Compare With The 2008 Crash? [Forbes]
5/14
05:14 pm
incy
Neutral
Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress [Yahoo! Finance]
5/14
05:00 pm
incy
Neutral
Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress
5/14
11:02 am
incy
Low
Company News For May 14, 2024 [Yahoo! Finance]
5/14
03:11 am
incy
Low
Stock market today: Asian shares mixed in muted trading after Wall Street barely budges [Yahoo! Finance Canada]
5/14
03:11 am
incy
Low
Stock market today: Asian shares mixed in muted trading after Wall Street barely budges [Financial Post (Toronto, Ontario, Canada)]
5/14
03:05 am
incy
Low
Stock market today: Asian shares mixed in muted trading after Wall Street barely budges [Yahoo! Finance]
5/13
08:10 am
incy
Low
Incyte jumps 6%, intends to buy back $2B stock [Seeking Alpha]
5/13
07:12 am
incy
Low
Incyte Announces Intention to Buy Back up to $2.0 Billion of its Common Stock [Yahoo! Finance]
4/30/2024
07:00 am
incy
-1.8%
MISS
2/13/2024
07:00 am
incy
0.2%
BEAT
10/31/2023
07:00 am
incy
3.0%
BEAT
8/1/2023
07:00 am
incy
-3.5%
BEAT
Earnings are essential to understanding the financial health of a company listed on any Stock Exchange. But what are Earnings, how are they calculated, when are they announced, and how are they used to make sound investment decisions? The answers are right here.
5/1
08:00 am
Maintains
Market Perform
Market Perform
BMO Capital
Low
1.6%
5/1
08:00 am
Maintains
Market Perform
Market Perform
BMO Capital
Low
1.6%
4/24
07:21 am
Maintains
Outperform
Outperform
Oppenheimer
Low
-0.9%
4/24
07:21 am
Maintains
Outperform
Outperform
Oppenheimer
Low
-0.9%
4/23
07:59 am
Initiates
Neutral
Cantor Fitzgerald
Low
-1.8%
4/23
07:02 am
Initiates
Neutral
Cantor Fitzgerald
Low
-1.9%
4/23
06:12 am
Initiates
VIEW
CANTOR FITZGERALD
Low
-1.9%
3/25
11:29 am
Reiterates
Sector Perform
Sector Perform
Royal Bank of Canada
Low
1.0%
3/25
11:29 am
Reiterates
Sector Perform
Sector Perform
Royal Bank of Canada
Low
1.0%
5/15
11:11 am
incy
Low
Form SC TO-I/A INCYTE CORP Filed by: INCYTE CORP
5/13
06:07 pm
incy
Low
Form SC 13D/A INCYTE CORP Filed by: BAKER BROS. ADVISORS LP
5/13
11:19 am
incy
Low
Form SC TO-I INCYTE CORP Filed by: INCYTE CORP
5/13
07:20 am
incy
Low
Form SC TO-C INCYTE CORP Filed by: INCYTE CORP
5/13
07:19 am
incy
Low
Form 8-K INCYTE CORP For: May 12
5/9
06:41 pm
incy
Low
Form SC 13D/A INCYTE CORP Filed by: BAKER BROS. ADVISORS LP
5/9
06:26 pm
incy
Low
Form 4 INCYTE CORP For: May 07 Filed by: Baker Brothers Life Sciences LP
4/30
04:03 pm
incy
Low
Form 10-Q INCYTE CORP For: Mar 31
4/30
07:10 am
incy
Low
Form 8-K INCYTE CORP For: Apr 30
Show more
Top News Gainers
4/5 Incyte Announces First Presentation of Phase 3 Data from the TRuE-AD Program of Ruxolitinib Cream at the Revolutionizing Atopic Dermatitis Virtual Symposium 7.1%
7/30 Incyte Reports 2019 Second Quarter Financial Results and Provides Updates on Key Clinical Programs 6.4%
3/13 Incyte Co. (NASDAQ: INCY) was upgraded by analysts at Bank of America Corp from a "neutral" rating to a "buy" rating. They now have a $83.00 price target on the stock. 6.4%
3/26 Incyte Names New Member to Its Board of Directors 5.9%
1/13 Incyte Co. (NASDAQ: INCY) had its "buy" rating re-affirmed by analysts at Cowen Inc. 5.7%
11/25 Data from Incyte’s Oncology Portfolio Accepted for Presentation at the 61st Annual ASH Meeting 5.3%
4/15 Form 4 INCYTE CORP For: Apr 13 Filed by: Pasquale Maria E 5.2%
2/18 Form 4 INCYTE CORP For: Feb 13 Filed by: Pasquale Maria E 4.0%
9/19 Form 4 INCYTE CORP For: Sep 18 Filed by: SWAIN PAULA J 4.0%
3/24 Blair likes Incyte in premarket analyst action [Seeking Alpha] 3.5%
Top News Decliners
1/2 Incyte Announces Results of Phase 3 Study of Itacitinib in Patients with Treatment-Naïve Acute Graft-Versus-Host Disease -9.4%
5/10 Form 4 INCYTE CORP For: May 09 Filed by: Iyengar Vijay K -6.1%
3/26 Form 8-K INCYTE CORP For: Mar 25 -5.6%
6/7 Form SC 13D/A INCYTE CORP Filed by: BAKER BROS. ADVISORS LP -5.0%
9/23 Incyte to Host Investor Conference Call from ESMO 2019 -4.6%
1/28 Incyte's skin disease drug meets main goal in late-stage study [Reuters] -3.8%
3/10 Incyte Joins Elite List Of Stocks With 95-Plus Composite Rating [Investor's Business Daily] -3.2%
9/27 Incyte Announces Positive Updated Results from Phase 2 Trial of Pemigatinib in Patients with Previously Treated, Advanced Cholangiocarcinoma -3.2%
9/12 Incyte Co. (NASDAQ: INCY) is now covered by analysts at BMO Capital Markets. They set a "market perform" rating on the stock. -3.1%
8/27 BriaCell Announces Participation at the 21st Annual Global Investment Conference in New York City September 8-10, 2019 -3.1%